Shares of MABWELL-B (02493) have risen more than 7%, moving against the broader market trend.

As of the latest update, the stock is up 6.54% to HK$23.78, with a trading volume of HK$8.6025 million.

The positive movement follows news that the company's self-developed antibody innovative drug, 9MW5211, has officially received approval from the National Medical Products Administration to conduct clinical trials targeting inflammatory bowel disease (IBD).

9MW5211 represents the world's first candidate drug targeting its specific mechanism to enter the clinical stage.

It is noteworthy that this drug had previously received FDA clearance to proceed with clinical trials for IBD in the United States.

In other recent developments, at the 2026 ASCO meeting, the company presented results from an Ib/II phase clinical study of its Nectin-4 ADC innovative drug, 9MW2821, in combination with toripalimab for treating patients with locally advanced or metastatic urothelial carcinoma.

This study was delivered as an oral presentation.

A separate Phase II clinical study evaluating the same combination for perioperative muscle-invasive bladder cancer was presented in a poster format.

Both studies demonstrated encouraging efficacy results alongside a favorable safety profile.